Subscribe to RSS Feed

Prostate Cancer Survival Rates Improved After Routine PSA Testing

The life-saving potential of the prostate-specific antigen (PSA) blood test is demonstrated by a Cleveland Clinic prostate cancer study released last summer, according to Dr. David Samadi, robotic prostate surgeon and Vice Chairman, Department of Urology and Chief of Robotics and Minimally Invasive Surgery at New York's Mount Sinai Medical Center.

The study, published August 2012 in the journal Urology, was designed to assess how the onset of routine PSA testing in the early 90s impacted long-term prostate cancer treatment outcomes. Data was reviewed from patients who underwent either prostate removal surgery or radiation for prostate cancer.

Researchers found an 82 percent 15-year metastasis-free survival rate in prostate cancer patients treated after routine PSA testing was implemented (1993-1996), compared with a 74 percent 10-year metastasis-free survival rate for patients treated before routine screenings (1986-1992).

Dr. Samadi said, "Men with prostate cancer are living longer and with excellent recovery odds. Early diagnosis a major factor in our success with this disease."

The Cleveland Clinic researchers compared data from more than 1,700 prostate cancer patients. The men were divided into groups of those treated in the years before PSA testing was routinely recommended for men and in the years after. The cases represented a range of low-, intermediate-, and high-risk disease progression and the benefit from PSA testing was present across all disease levels.

Despite the positive indications found in similar studies comparing pre- and post-PSA data, many men are undecided about whether or not to screen. In May 2012, the U.S. Preventive Services Task Force recommended against PSA-based screening for men regardless of age (not including surveillance after diagnosis or treatment of prostrate cancer). The American Cancer Society recommends that men considering prostate cancer screening make informed decisions based on available information, discussion with their doctor, and their own views on the side effects of screening and treatment.

Prostate cancer experts remain divided on the topic of screening. "Early diagnosis opens a valuable window for treatment, but it's important for men to understand that the PSA is not a one-time test. There's no positive-or-negative when it comes to prostate cancer," explains Dr. Samadi. "We monitor PSA results, over a period of years, to identify when a man's level may be elevated so that we can explore further and, if warranted, address the cancer via robotic prostate removal or other means of treatment."

Back to Press Releases

Bookmark Using:
Facebook Twitter LinkedIn Email Yahoo

Share on Facebook

Call to Make an Appointment With Dr. David Samadi:


Click the contact link to learn how Dr. Samadi can help treat your prostate cancer and give you back your quality of life.

* The benefits of robotic surgery cannot be guaranteed as surgery is both patient and procedure specific. Previous surgical results do not guarantee future outcomes.

Mario J., USA

Several weeks ago I found myself not waking from a nightmare but waking into one. This was after being diagnosed with cancer. My life was spiraling out of control and reaching the epitome of despair. In a true sense of the word, I was experiencing an existential crisis. At moments I even questioned whether my life was worth going forward.

D. L., New Jersey, USA

"You are the all around Doctor that together with your robotic surgery I will recommend without a doubt".

J. B., New York, USA

"I wanted to take the opportunity to thank you for the kindness and caring that you've shown my family and most importantly my father during this difficult time"

J. M., Los Angeles, California

"My PSA now is